Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective open-label trial of guselkumab for ultrasound-proven enthesitis in psoriatic arthritis
2024-512459-19-00Phase 4Authorised
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of guselkumab in psoriatic arthritis (PsA) and plaque psoriasis, sponsored by Universitätsklinikum Erlangen. Primary endpoint: Resolution of enthesitis at week 24. Planned start Jun 2024; status: authorised.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)plaque psoriasis
Beyond the preview
Go deeper on 2024-512459-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512459-19-00.